Results from a new research about the preclinical development of a new targeted therapeutic for the treatment of pediatric cancer neuroblastoma have been published on Cancers.

The first author of the research is Dr. Emily Capone and the work was coordinated by Dr. Gianluca Sala, both members of Laboratory of Clinical Biochemistry and Molecular Biology directed by Prof. Vincenzo De Laurenzi. The study on the new compound, named 1959-sss/DM3, was done in collaboration with “Mediapharma srl”, which provided the reagent, and research teams from “University of L’Aquila”, “Giannina Gaslini Institute” of Genova and “Brunel University” of London.

Researchers showed that the Antibody-Drug Conjugate 1959-sss/DM3, a biopharmaceutical drugs designed as a targeted therapy, possesses a potent, specific and durable antitumor activity in neuroblastoma preclinical models, providing a rationale for further clinical development of this compound.

The study was mainly carried out at CAST with the support of AIRC and Associazione Italiana for Neuroblastoma.